Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $15.03 million versus the consensus estimate of $14.62 million.

2023 Financial Guidance

The Company anticipates DEXTENZA net product revenue guidance for the full year 2023 to come in at the upper end of the current $55 and $60 million range provided by the Company. The current range represents anticipated growth of approximately 10% to 20% over 2022. The growth is anticipated to be driven by sales of DEXTENZA for the treatment of post-surgical inflammation and pain in the ASC setting.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.